The UK's pharmaceutical sector dragged the FTSE deep into the red this morning after US giant AbbVie said it is reconsidering the planned takeover of Shire, casting doubts over elevated share prices.
AbbVie agreed a takeover of UK-listed Shire for $54bn this summer, but is now reconsidering this plan after the US Treasury moved to restrict 'tax inversion' deals last month. The new tax crackdown will make the takeover far less lucrative for the US-based pharmaceutical, as it will no longer be able to take advantage of lower corporate tax rates in the UK. In a statement issued this morning, AbbVie said its board of director will meet next week to reconsider the proposed deal. Shire said it wants the takeover to proceed as planned. Shire was the biggest faller on the FTSE 100 this...
To continue reading this article...
Join Investment Week for free
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes